Recombinant human type II tumor necrosis factor receptor-antibody fusion protein for injection (Etanercept, Ixep) is mainly used for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Etanercept is a drug that stops joint degeneration and treats moderate to severe rheumatoid arthritis; it is also a drug that can treat ankylosing spondylitis and is also effective in treating severe psoriasis. Ixepro specifically binds to tumor necrosis factor (TNF) in the body and negatively regulates the activity of TNF, thereby inhibiting the inflammatory response within the human bone and joint.